Oral-paliperidone-induced tardive dyskinesia: a case report

Abstract

Objectives: Tardive dyskinesia (TD) is generally considered the most severe extrapyramidal sequelae of antipsychotic treatments.

Method: Case report.

Results: We present a 20-year-old woman with previous treatment of risperidone 6-7 mg daily for approximately 4 years. She developed TD 2 years later after switching to paliperidone 9 mg daily. To the best of our knowledge, she is the first case report of having direct paliperidone-induced TD. Immediate treatments including paliperidone dose reduction to 6 mg daily, clonazepam 1.5 mg daily and trihexyphenidyl 2 mg daily were performed for 1 month, and her symptoms were relieved eventually after switching to clozapine 75 mg daily.

Conclusion: Although second-generation antipsychotics such as paliperidone are considered to have a lowered risk of developing TD, this case could bring awareness to clinicians of the possibility of TD with the use of any antipsychotics.